Company intelligence / Profile preview
Parabilis Medicines
Cambridge, Massachusetts, United Statesparabilismed.com ↗
- Ownership
- Public · PBLS
- Employees
- ~100
- Development stage
- Phase 1
01
Overview
The company's lead candidate FOG-001 is in Phase 1/2 clinical trials for colorectal cancer and other solid tumors. In April 2025, they reported positive proof-of-mechanism data for their ERG degrader program showing tumor growth inhibition in multiple mouse models of prostate cancer.
- Therapeutic areas
- Oncology
- Modalities
- Helicon peptide therapeuticscell-penetrating miniproteins (CPMPs)peptide degradersradioligand therapeutics
- Industry
- Biotech
02
Drug pipeline
6 assets5 more assets in the full pipeline.
Request access →03
Financials
- Market cap
- $4.6B
- Total revenue
- $148K
- Enterprise value
- $3.6B
Beyond the preview
Go deeper on Parabilis Medicines.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Parabilis Medicines.